425: AI Drug Discovery Pioneer Nanyang Biologics to Go Public

Nanyang Biologics, an AI-driven drug discovery company, will go public via a business combination with SPAC RF Acquisition Corp II in a $1.5 billion transaction.

Summary

• RF Acquisition Corp II (RFAI) and Nanyang Biologics Pte. Ltd. (Nanyang) have entered into a definitive Business Combination Agreement.
• The transaction will result in Nanyang becoming a publicly listed company on Nasdaq under the reserved ticker symbol 'NYB'.
• The proposed transaction values Nanyang Biologics at approximately $1.5 billion in pre-transaction equity value.
• Nanyang's existing shareholders, including The9 Limited and Mercatus Capital, will roll over 100% of their equity and retain a majority of the combined company's outstanding shares.
• The combined company will be led by Nanyang's current Group Chairman, Roland Ong, and Professor Li Hoi Yeung, Lead Principal Investigator of the NYB-NTU joint laboratory.
• The board of directors of the combined entity (PubCo) will consist of seven directors, with six designated by Nanyang and one by the Sponsor (Alfa 24 Limited).
• The closing of the transaction is expected in the first or second quarter of 2026, subject to shareholder approvals and customary closing conditions.

Sentiment

Score: 8

Explanation: The announcement of a definitive business combination for Nanyang Biologics is highly positive. The company demonstrates strong technological innovation with its AI platform, a promising drug pipeline targeting significant unmet medical needs, and strategic partnerships. The valuation and planned Nasdaq listing provide a clear path for growth and capital access, indicating strong future potential despite inherent biotech R&D risks.

Positives

• Nanyang Biologics operates an industry-recognized AI Drug Discovery Platform, Vecura AI, powered by its proprietary DTIGN engine.
• The DTIGN engine outperformed competitors by 27% in benchmarking tests and was awarded 1st Prize at the SuperAI Genesis Startup Competition 2025 among over 700 global startups.
• Nanyang's flagship product candidate, NB-A002, is a first-in-class oncology therapeutic targeting the previously undruggable ILF2 protein, with potential treatments for various solid tumors.
• NB-A002 is positioned to address a significant unmet global demand in the DNA Damage Response (DDR) therapy market, valued at $8.3 billion today and projected to reach $19.5 billion by mid-2030s.
• Nanyang has a pioneering joint laboratory collaboration with Nanyang Technological University Singapore (NTU), a global AI powerhouse, to develop next-generation AI engines and expand discovery.
• The company holds a growing portfolio of patents across its drug-candidate pipeline and proprietary nutraceuticals.
• Nanyang's pipeline includes nature-inspired small molecules like NB-B101 (solid tumors), NB-C201 (cardiovascular health), and NB-C301 (mental health), all progressing through preclinical stages.
• The lead molecule NB-A002 has received a clinical trial invitation from the head of oncology at a top university, indicating strong scientific interest and potential.
• Existing Nanyang shareholders will retain a majority stake, demonstrating confidence in the company's future.

Negatives

• Nanyang Biologics has a history of losses, as noted in the risk factors.
• The consummation of the transaction is subject to various conditions, including regulatory and shareholder approvals, which may not be satisfied.
• Forward-looking statements and financial forecasts are subject to significant risks and uncertainties, and actual results may differ materially.

Risks

• Changes in domestic and foreign business, market, financial, political, and legal conditions could adversely affect the combined company.
• The inability of the parties to successfully or timely consummate the Business Combination, including due to regulatory delays or failure to obtain shareholder approvals.
• The Business Combination may disrupt current plans and operations of RFAI or Nanyang.
• Nanyang's ability to grow and manage growth profitably and retain key employees, including its chief executive officer and executive team, is crucial.
• The inability to obtain or maintain the listing of the post-acquisition company's securities on Nasdaq or NYSE.
• Failure to realize the anticipated benefits of the Business Combination.
• Uncertainty of the projected financial information with respect to Nanyang.
• The amount of redemption requests made by RFAI's shareholders could impact the funds available in the trust account.
• Nanyang's ability to attract new and retain existing customers in a cost-effective manner.
• Competitive pressures and disruptions in the biotechnology and drug discovery industries.
• Nanyang's ability to achieve profitability despite a history of losses.
• The success of Nanyang's new product or service offerings and its ability to produce accurate forecasts of operating and financial results.
• Fluctuations in foreign currency exchange rates and Nanyang's ability to raise capital.
• Changes in regulatory environments (e.g., anti-trust laws, foreign ownership restrictions, tax regimes) in countries where Nanyang operates.
• The impact of the COVID-19 pandemic on Nanyang's business.
• Disruptions to information technology systems and networks, and the ability to protect intellectual property.
• Potential and future litigation that the Group may be involved in.
• Unanticipated losses, write-downs, restructuring, impairment, or other charges, taxes, or liabilities.

Future Outlook

The combined company, Nanyang Biologics, is expected to be listed on Nasdaq under the ticker symbol 'NYB'. It aims to accelerate the discovery of more effective drug molecules and identify active ingredients from natural sources for use in both pharmaceuticals and traditional medicine. The pioneering collaboration with Nanyang Technological University Singapore (NTU) will continue to develop next-generation AI engines and expand discovery into biologics and other large-molecule modalities, supporting a vision of extending human longevity.

Management Comments

• Tse Meng Ng, Chairman and CEO of RF Acquisition, stated: "We are thrilled to partner with Roland, Professor Li, and the NYB team at this pivotal moment in their growth journey. NYB has built a truly differentiated AI-powered drug discovery platform, combining world-class research capabilities with a strong pipeline of therapeutic candidates. We believe NYB is uniquely positioned to transform the future of medicine by addressing areas of high unmet medical need. This transaction reflects our confidence in NYB's ability to create lasting value for patients, shareholders, and the broader healthcare ecosystem. We look forward to supporting the Company as it enters the public markets and executes on its vision of reshaping healthcare through innovation."
• Roland Ong, Group Chairman of NYB, commented: "We are delighted to announce our business combination with RF Acquisition Corp II, marking an important milestone in NYB's journey. AI-driven drug discovery is breaking through barriers that have long hindered the advancement of medicine, significantly reducing R&D time and costs while opening new opportunities for humanity to pursue longevity. Our proprietary DTIGN platform has mapped vast numbers of natural compounds and identified promising candidates, strengthening the feasibility of a new era of drug development. On top of that, our lead molecule NB-A002 introduces a novel approach to treating solid tumors, and we are honored to have received a clinical trial invitation from the head of oncology at one of the world's top universities. At the same time, our pioneering collaboration with NTU continues to propel us forward, building the next generation of AI engines and expanding discovery into biologics and other modalities. Together, these achievements affirm our vision of reshaping healthcare through innovation."

Industry Context

The announcement positions Nanyang Biologics at the forefront of the rapidly growing AI-driven drug discovery and biotechnology sector. By integrating traditional medicine wisdom with advanced AI, Nanyang aims to significantly reduce R&D costs and accelerate the identification of drug candidates. Its focus on the DNA Damage Response (DDR) therapy market, particularly for HRD cancers, targets a high-unmet medical need within oncology, a sector experiencing substantial innovation and investment. The collaboration with a top-ranked AI university (NTU) further solidifies its competitive standing in a highly competitive and capital-intensive industry.

Comparison to Industry Standards

• Nanyang's patented Drug-Target Interaction Graph Neural Network (DTIGN) engine outperformed competitors by 27% in benchmarking tests, as published in the IEEE magazine.
• The DTIGN engine was awarded 1st Prize at the SuperAI Genesis Startup Competition 2025 among over 700 global startups, highlighting its innovative edge.
• The collaboration with Nanyang Technological University Singapore (NTU), ranked 2nd worldwide for AI by the U.S. News & World Report 2025, provides a strong academic and research foundation.
• NB-A002 is described as a 'first-in-class' oncology therapy and offers a 'superior alternative to PARP inhibitors' for HRD cancers, suggesting a significant advancement over existing treatments.

Management Changes

Corporate Governance

Related Party Transactions

• Certain Nanyang shareholders (including The9 Limited, Mercatus Capital, and Ong Toon Wah) entered into a Company Holders Support and Lock-Up Agreement, agreeing to vote in favor of the transaction and a 24-month lock-up on PubCo shares.
• Alfa 24 Limited (Founder/Sponsor) entered into a Founders Support and Lock-Up Agreement, agreeing to vote in favor of the transaction and a 24-month lock-up on PubCo shares.
• Related Party Agreements listed in Section 5.13(a)(vi) of the Company Disclosure Letter are to be terminated or settled at or prior to the Amalgamation Closing, except as otherwise disclosed.
• Sponsor Affiliate Agreements will be terminated effective as of the Amalgamation Effective Time, releasing parties from future obligations, with exceptions for certain existing rights and fraud claims.

Stakeholder Impact

• **Shareholders (RF Acquisition Corp II)**: Will exchange their shares for PubCo shares and have the opportunity to redeem their shares. They will vote on the business combination and other transaction proposals.
• **Shareholders (Nanyang Biologics)**: Will receive newly issued PubCo Shares, retaining a majority ownership in the combined company, subject to a 24-month lock-up period for certain shareholders.
• **Employees (Nanyang Biologics)**: The existing management team will continue to lead the combined company, and an equity incentive plan will be adopted, potentially benefiting employees.
• **Customers/Patients**: The transaction aims to accelerate drug discovery and development, potentially leading to new pharmaceuticals and personalized healthcare solutions for high-unmet medical needs.
• **Underwriters of RFAI's IPO**: Will receive deferred underwriting commissions from the Trust Account.
• **Creditors of Nanyang/Amalgamation Sub**: Their written consent to the Amalgamation will be sought, and obligations will be addressed to prevent delays in the transaction.

Next Steps

• PubCo will file a registration statement on Form F-4 with the SEC, including a proxy statement for RFAI shareholders.
• RFAI will mail the proxy statement/prospectus to its shareholders and hold a meeting to vote on the Transaction Proposals.
• Nanyang will solicit and obtain Company Shareholder Approval for the Amalgamation Proposal.
• The Amalgamation Closing is expected in the first or second quarter of 2026.
• PubCo Shares are expected to be approved for listing on Nasdaq (or NYSE) under the ticker symbol 'NYB'.
• PubCo will adopt an equity incentive plan for awards of up to 10% of outstanding PubCo Shares.
• PubCo will purchase and fully fund a six-year tail directors and officers liability insurance policy.
• PubCo will enter into customary indemnification agreements with its post-Amalgamation Closing directors and officers.
• Nanyang aims to accelerate the discovery of more effective drug molecules and identify active ingredients from natural sources for pharmaceuticals and traditional medicine.
• The NYB-NTU collaboration will continue to develop next-generation AI engines and expand discovery into biologics and other modalities.

Key Dates

Recommendation

Nanyang Biologics presents a compelling investment opportunity due to its innovative AI-driven drug discovery platform (DTIGN), which has demonstrated superior performance and received industry recognition. The company's lead oncology candidate, NB-A002, targets a substantial and growing market with high unmet needs, offering a potential 'first-in-class' treatment. The strategic collaboration with Nanyang Technological University further enhances its research capabilities. The business combination with RF Acquisition Corp II provides a clear pathway to public listing on Nasdaq, facilitating access to capital for pipeline acceleration. While early-stage and carrying inherent biotech R&D risks, the strong technological foundation, significant market potential, and experienced leadership team position Nanyang Biologics for substantial long-term growth, making it an attractive 'buy' for growth-oriented investors.

Keywords

Nanyang Biologics, RF Acquisition Corp II, SPAC, Business Combination, AI Drug Discovery, Biotechnology, Oncology, NB-A002, DTIGN, Nasdaq Listing, Merger, Biologics, Pharmaceuticals, Natural Compounds, DDR Therapy